# US 2019/0167759 A1 · Antimicrobial compositions and methods of use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167759 A1 - Document ID: US20190167759A1 - Status: Published application - Kind: A1 - Application number: 16/241,316 - Filed: 2019-01-07 - Published: 2019-06-06 - Earliest claimed: 2011-10-07 - Assignees: Morehouse School of Medicine - Applicants: Morehouse School of Medicine - Inventors: Vincent C. BOND; Michael Powell; Ming Bo Huang; Syed Ali; Martin N. Shelton - Web page: https://patentgrep.com/patent/US20190167759A1 ## CPC - A61K 38/162: {from virus} - A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - C07K 7/06: having 5 to 11 amino acids - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - C12N 2740/16032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif. ## Claims ### Claim 1 A method of treating a microbial infection, comprising: administering to a subject in need thereof an effective amount of an antimicrobial peptide comprising a first antimicrobial domain comprising at least two VGVSV (SEQ ID NO:2) motifs. ### Claim 2 (depends on 1) The method of claim 1, wherein said antimicrobial peptide has a length of 10-200 amino acids. ### Claim 3 (canceled) ### Claim 4 (depends on 1) The method of claim 1, wherein said antimicrobial peptide comprises at least one VGVSV motif at the N-terminal. ### Claim 5 (depends on 1) The method of claim 1, wherein said antimicrobial peptide comprises at least one VGVSV motif at the C-terminal. ### Claim 6 (depends on 1) The method of claim 1, wherein said antimicrobial peptide comprises the amino acid sequence of VGVSVAAVGVSV (SEQ ID NO:4). ### Claim 7 (depends on 1) The method of claim 1, wherein said antimicrobial peptide further comprises a second antimicrobial domain, wherein said second antimicrobial domain is different from said first antimicrobial domain. ### Claim 8 (depends on 1) The method of claim 1, wherein said antimicrobial peptide further comprises a cell penetrating peptide (CPP) domain. ### Claim 9 (depends on 1) The method of claim 1, wherein said antimicrobial peptide further comprises a targeting domain. ### Claim 10 (depends on 1) The method of claim 1, wherein said antimicrobial peptide is administered in combination with another antimicrobial agent. ### Claim 11 (depends on 10) The method of claim 10, wherein said another antimicrobial agent is another antimicrobial peptide. ### Claim 12 (depends on 10) The method of claim 10, wherein said another antimicrobial agent is an in vivo expression vector encoding said antimicrobial peptide. ### Claim 13 (depends on 10) The method of claim 10, wherein said antimicrobial peptide is a PEGylated peptide. ### Claim at position 14 14-18. (canceled) ### Claim 19 A pharmaceutical composition for treating microbial infection, comprising: (1) an antimicrobial peptide comprising a first antimicrobial domain comprising two VGVSV (SEQ ID NO:2) motifs, and a cell penetrating peptide (CPP) domain and/or a targeting domain; and (2) a pharmaceutically acceptable carrier. ### Claim 20 (depends on 19) The pharmaceutical composition of claim 19, wherein said antimicrobial peptide is a PEGylated peptide. ### Claim 21 (depends on 19) The pharmaceutical composition of claim 19, wherein said antimicrobial peptide further comprises a second antimicrobial domain, wherein said second antimicrobial domain is different from said first antimicrobial domain.